Monday 30 May
Education Session
08:00-09:00
Registration
09:00-10:30
Parallel 1a: Gene delivery platform
Chairs: Virginia Haurigot, Spark Therapeutics
09:00 Virginia Haurigot, Spark Therapeutics
INV01 AAV vectors, from basics to challenges
09:25 Xavier Anguela, Ask Bio ⓘ
INV02 Non-viral gene transfer for rare diseases
09:50 Pedro Berraondo, Program of Immunology and Immunotherapy, Cima Universidad de Navarra ⓘ
INV03 Advances in mRNA-based therapeutics
10:15 Round Table
09:00-10:30
Parallel 1b: Cellular Therapy
Chairs: Javier Garcia Castro, Instituto de Salud Carlos III, Madrid
09:00 Pablo Menendez, Josep Carreras Leukaemia Research Institute, Barcelona ⓘ
INV04 CAR-based adoptive T-cell immunotherapies
09:25 Aida Platero-Luengo, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC ⓘ
INV05 Crossing new frontiers in regenerative medicine: the reprogramming technology in cell therapy and aging
09:50 Javier Garcia Castro, Instituto de Salud Carlos III, Madrid ⓘ
INV06 The state of the art in Cellular Therapy
10:15 Round Table
10:30-11:00
Break
Monday 30 May
12:30-13:30
Lunch and Biennial Congress Registration
12:30-13:30
Plenary 1: Inaugural session
Chair: Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona; JuanJo Toledo-Aral, Universidad de Sevilla
13:30 Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona ⓘ
SETGYC since 2019: Society update
13:45 Mariano Esteban, CNB-CSIC, Cantoblanco, Madrid
INV13 Lessons and challenges in the development of the vaccine MVA-CoV2-S/COVID-19
14:45-16:15
Parallel 3a: Gene delivery platforms
Chair: Karim Benabdellah, GENYO, Granada
14:45 Els Verhoeyen, ENS Lyon, Université de Nice ⓘ
INV15 Novel lentiviral pseudotypes for T and NK cell gene therapy and ‘nanoblades’ for efficient gene editing in hematopoietic gene therapy target cells and organoids
15:15 Pedro Berraondo, Program of Immunology and Immunotherapy, Cima Universidad de Navarra
INV16 Messenger RNA in cancer immunotherapy
15:45 Pilar Martin Duque, Universidad de Zaragoza
OR01 Use and isolation of maternal milk exosomes: New vector for genetic hNIS therapy and diagnostic in oncology
16:00 Carlos Blanco-Benitez, LentiStem Biotech. GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government.PTS Granada
OR02 Lent-On-Plus: An all-in-one transactivator-free doxycycline inducible LVs ready for clinical applications
14:45-16:15
Parallel 3b: Pluripotent stem cells & organoids
Chair: Ricardo Pardal, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/
14:45 Nuria Montserrat, Institute for Bioengineering of Catalonia (IBEC)
INV17 Human pluripotent stem cells derived organoids: challenges and opportunities to study human development and disease
15:15 Isabel Fariñas, Departamento de Biología Celular, Biología Funcional y Antropología Física, Universidad de Valencia ⓘ
INV18 The impact of neural stem cell heterogeneity on niche dynamics
15:45 Beatriz Fernandez-Muñoz, Red Andaluza de Diseño y Traslación de Terapias Avanzadas, Sevilla
OR03 Using organoids to evaluate safety and potency of cell therapies
16:00 Ainhoa Irastorza-Lorenzo, Biodonostia Institute, San Sebastian
OR04 Development of biomimetic tympanic membrane substitutes for the treatment of chronic perforations
16:15-17:15
Break and Poster Session 1
Tuesday 31 May
08:00-09:00
Registration
09:00-09:30
Plenary 3: Safety
Chair: Juan Bueren, CIEMAT, Madrid
09:00 Zoltan Ivics, Paul Ehrlich Institute, Langen ⓘ
INV26 Non-viral engineering of therapeutic cells with the Sleeping Beauty transposon system
09:30-10:00
Advances therapies move to patients
Chair: Gloria Gonzalez-Aseguinolaza, University of Navarra, Pamplona
09:30 Juan Bueren, CIEMAT, Madrid ⓘ; Cristian Smerdou, CIMA Universidad de Navarra, Pamplona
INV27 Towards the implementation of gene therapy in the clinical practice
10:00-11:30
Parallel 5a: CAR-T cells
Chair: José Antonio Pérez-Simón, Institute of Biomedicine of Sevilla
10:00 Antonio Perez-Martinez, Hospital Universitario La Paz, Madrid ⓘ
INV28 Cell therapy based on the Chimeric receptor NKG2D
10:30 Valentin Ortiz, Hospital Clínic de Barcelona
INV29 CART19-BE-01: A European academic trial on the administration of ARI-0001 cells in patients with acute lympoblastic leukemia and other CD19+ lympoproliferative disorders
11:00 Angel Martin Mallo, Cima Universidad de Navarra. IdiSNA.
OR09 Effect of the disease stage over the phenotype and functionality of CAR-T cells in multiple myeloma patients
11:15 Diego Sanchez-Martínez, Josep Carreras Leukemia Research Institute
OR10 Efficient treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-AntigenA T cell engagers
10:00-11:30
Parallel 5b: Cell and gene therapy of Neural diseases
Chair: Juan José Toledo-Aral, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla
10:00 Benedikt Berninger, Institute of Psychiatry, Psychology & Neuroscience Centre for Developmental Neurobiology & MRC Centre for Neurodevelopmental Disorders, King's College London ⓘ
INV30 Advancing in vivo glia-to-neuron reprogramming as an innovative approach for brain repair: promises, disappointments, and breakthroughs
10:30 Juan Ruiz, Forge Therapeutics
INV31 The RESKUE Trial - a Phase 1/2 Clinical Trial for Patients with Krabbe Disease
11:00 Sergi Verdés, Institut de Neurociències (INc), Universitat Autònoma de Barcelona (UAB)
OR11 Gene therapy for ALS by specifically overexpressing a pleiotropic chronokine, secreted α-Klotho (s-KL), in skeletal muscles
11:15 Nieves Iria Domínguez-García, Instituto de Biomedicina de Sevilla (IBiS)
OR12 Pathophysiological alterations of regulatory T cells in Parkinson's disease and generation of aSyn-CAR-Tregs as a novel therapeutic approach
Wednesday 1 June
Ex Vivo and In Vivo Gene Editing: Present and Future Clinical Applications
08:30-09:00
Registration
09:00-10:30
Plenary 6: New gene editing tools
Chairs: Raul Torres, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid; Marc Güell, Universitat Pompeu Fabra, Barcelona
09:00 Julian Grünewald, Technical University of Munich
INV48 Engineered CRISPR prime editors with compact, untethered reverse transcriptases
09:30 Pilar Puig-Serra, CNIO, Madrid ⓘ
INV49 Targeting and detection of cancer fusion oncogenes using CRISPR/Cas13
10:00 Guillermo Güenechea Amurrio, CIEMAT, CIBERER, Madrid
OR20 Editing of Telomerase RNA Component gene in hematopoietic stem cells: An alternative tool to treat bone marrow failure in patients with autosomal dominant dyskeratosis congenita
10:15 Isabel Ojeda-Perez, CIEMAT, CIBERER, Mardid
OR21 Studying Hematopoietic Stem Cell clonality in Gene Editing Strategies using DNA Barcoding
10:30-12:00
Plenary 7: Gene editing ex vivo
Chairs: Francisco Martin, Genyo, Granada; Paula Rio, CIEMAT, Madrid
10:30 Annarita Miccio, Imagine Institute, Paris
INV50 Genome editing approaches for beta-hemoglobinopathies
11:00 Alessia Cavazza, UCL, London ⓘ
INV51 Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome
11:30 Matthew Porteus, Stanford University ⓘ
INV52 Genome Editing of Hematopoietic Stem Cells
12:00-12:30
Break
12:30-13:30
Plenary 8: in vivo Gene editing applications
Chairs: Gloria Aseguinolaza, University of Navarra, Pamplona; Juan Bueren, CIEMAT, Madrid
12:30 Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona ⓘ
INV53 In vivo gene editing to treat Primary hyperoxaluria type I
13:00 Jordi Barquinero, Vall d'Hebron Research Institute, Barcelona ⓘ
INV54 In vivo gene editing for Mitochondrial NeuroGastroIntestinal Encephalomyopathy
13:30 Ignacio Perez de Castro, Instituto de Salud Carlos III, Madrid
OR22 CRISPR-based strategies revert the LMNAᴿ²⁴⁹ᵂ induced phenotype both in cultured cells and in vivo